{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Stage+III", "query": { "condition": "Unresectable Stage III" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 637, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Stage+III&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T02:32:54.756Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03102242", "title": "Atezolizumab Immunotherapy in Patients With Advanced NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 64, "start_date": "2017-11-01", "completion_date": "2022-10-01", "has_results": true, "last_update_posted_date": "2023-05-24", "last_synced_at": "2026-09-25T02:32:54.756Z", "location_count": 13, "location_summary": "Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Brewer", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03102242" }, { "nct_id": "NCT03641313", "title": "Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Berzosertib", "type": "DRUG" }, { "name": "Computed Tomography Assisted Biopsy", "type": "PROCEDURE" }, { "name": "Endoscopic Biopsy", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-11-16", "completion_date": "2027-01-28", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-25T02:32:54.756Z", "location_count": 31, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03641313" }, { "nct_id": "NCT00289627", "title": "A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "ipilimumab (MDX-010, BMS-734016)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2006-04", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2016-09-28", "last_synced_at": "2026-09-25T02:32:54.756Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • San Francisco, California • Santa Monica, California + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00289627" }, { "nct_id": "NCT05694871", "title": "Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Dedifferentiated Liposarcoma", "Locally Advanced Dedifferentiated Liposarcoma", "Metastatic Dedifferentiated Liposarcoma", "Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Unresectable Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen collection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2023-06-07", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-25T02:32:54.756Z", "location_count": 194, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05694871" }, { "nct_id": "NCT06624644", "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Melanoma (Skin Cancer)", "Melanoma Stage IIIB-IV", "Cutaneous Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "LNS8801", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Chemotherapy (dacarbazine or temozolomide)", "type": "DRUG" }, { "name": "Immunotherapy (Pembrolizumab)", "type": "BIOLOGICAL" }, { "name": "Immunotherapy (nivolumab and relatlimab)", "type": "BIOLOGICAL" }, { "name": "Immunotherapy (ipilimumab and nivolumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Linnaeus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2025-08-06", "completion_date": "2031-02", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-25T02:32:54.756Z", "location_count": 9, "location_summary": "Newport Beach, California • San Francisco, California • Stanford, California + 6 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06624644" }, { "nct_id": "NCT03620019", "title": "Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage Iii", "Melanoma Stage Iv", "Melanoma", "Melanoma (Skin)", "Cutaneous Melanoma" ], "interventions": [ { "name": "Denosumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 25, "start_date": "2018-09-10", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-25T02:32:54.756Z", "location_count": 2, "location_summary": "Manchester, New Hampshire • Chapel Hill, North Carolina", "locations": [ { "city": "Manchester", "state": "New Hampshire" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03620019" }, { "nct_id": "NCT00496756", "title": "Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 14, "start_date": "2007-03-01", "completion_date": "2014-04-25", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-09-25T02:32:54.756Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00496756" }, { "nct_id": "NCT01739439", "title": "Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acinar Cell Adenocarcinoma of the Pancreas", "Duct Cell Adenocarcinoma of the Pancreas", "Stage IIB Pancreatic Cancer", "Stage III Pancreatic Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "hyperfractionated radiation therapy", "type": "RADIATION" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "radiosurgery", "type": "RADIATION" }, { "name": "diffusion-weighted magnetic resonance imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2013-05", "completion_date": "2015-12-01", "has_results": false, "last_update_posted_date": "2019-07-29", "last_synced_at": "2026-09-25T02:32:54.756Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01739439" }, { "nct_id": "NCT04534205", "title": "A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Unresectable Head and Neck Squamous Cell Carcinoma", "Metastatic Head and Neck Cancer", "Recurrent Head and Neck Cancer" ], "interventions": [ { "name": "BNT113", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2021-01-07", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-25T02:32:54.756Z", "location_count": 15, "location_summary": "Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04534205" }, { "nct_id": "NCT00654160", "title": "Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anal Cancer", "Carcinoma of the Appendix", "Colorectal Cancer", "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Gastric Cancer", "Gastrointestinal Carcinoid Tumor", "Gastrointestinal Stromal Tumor", "Liver Cancer", "Pancreatic Cancer", "Small Intestine Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 7, "start_date": "2008-06", "completion_date": "2012-12-03", "has_results": false, "last_update_posted_date": "2017-05-25", "last_synced_at": "2026-09-25T02:32:54.756Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654160" } ] }